ThursdayJan 08, 2026 12:00 am

ParaZero Technologies Ltd. (NASDAQ: PRZO) Is ‘One to Watch’

ParaZero operates as a defense aerospace company specializing in multi-layered Counter-UAS solutions for modern battlefield and homeland security environments. The DefendAir platform offers three complementary interception layers (airborne, turret-based, and hand-held) providing forces with flexible, low-collateral responses to diverse hostile drone threats. Company-reported demonstrations with Israeli defense authorities have shown effective real-time interception across fast, maneuverable, and RF-denied drone scenarios. DropAir delivers validated precision-delivery capability for medical and tactical supplies, including successful collaboration with the Israeli Ministry of Defense and the IDF Medical Corps. Rising global demand for cost-effective and scalable Counter-UAS systems positions ParaZero for continued expansion across defense…

Continue Reading

WednesdayJan 07, 2026 9:00 am

LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Is ‘One to Watch’

LIXTE is advancing a first-in-class PP2A inhibitor platform designed to enhance, rather than replace, established chemotherapy and immunotherapy regimens. The company is conducting multiple active clinical trials in solid tumors with significant unmet medical need, supported by academic and industry collaborations. LIXTE’s scientific strategy is protected by a comprehensive patent portfolio, with management noting no known direct competitors targeting PP2A inhibition. Strategic actions in 2025, including the acquisition of Liora Technologies and a registered direct offering completed in December 2025, reflect an effort to broaden capabilities and strengthen operational flexibility. Expansion of the ovarian clear cell carcinoma trial in December…

Continue Reading

WednesdayJan 07, 2026 9:00 am

Preclinical Study Suggests Combo Therapy Could Treat Glioblastoma

University of North Carolina researchers have developed a combination treatment that shows remarkable promise against glioblastoma, an aggressive brain cancer with dismal survival rates. The therapy paired a standard chemotherapy drug with a laboratory chemical called EdU to produce unprecedented results in preclinical models. Nobel Prize winner Aziz Sancar led the research and the findings were published in the journal Proceedings of the National Academy of Sciences. His team tested EdU alongside temozolomide, known as TMZ, across multiple glioblastoma models. The concept is straightforward: combining these two compounds can destroy tumors and prevent death, Sancar explained. Together, the drugs demonstrated…

Continue Reading

Contact us: (512) 354-7000